Significance of plasma miR-363-3p expression in multiple myeloma and its relationship with prognosis
-
摘要: 目的：分析多发性骨髓瘤（MM）患者血浆微小核糖核酸-363-3p （miR-363-3p）表达意义，并评估其与预后关系。方法：回顾性分析北京航天总医院106例MM患者临床资料，并纳入32例健康体检者作为对照组，记录2组血浆miR-363-3p表达水平差异。根据MM患者血浆miR-363-3p表达水平分为高表达组（≥平均值）和低表达组（<平均值），比较2组临床特征及疗效，并评估MM患者血浆miR-363-3p表达水平与临床特征、疗效的相关性；使用Kaplan-Meier生存分析法评估2组预后生存情况。结果：MM患者血浆miR-363-3p相对表达量显著低于对照组（P<0.05）。高表达组与低表达组间性别、年龄、免疫球蛋白分型、DS分期及血钙、血红蛋白水平比较，差异无统计学意义（P>0.05）；但2组间国际分期体系（ISS）分期存在显著差异（P<0.05），且高表达组临床疗效显著高于低表达组（P<0.05）。经Spearman秩相关分析发现，MM患者血浆miR-363-3p表达水平与ISS分期呈显著负相关（r=-0.421，P<0.05），与临床疗效呈显著正相关（r=0.533，P<0.05）。随访36个月时，高表达组生存31例（56.36%），低表达组生存18例（35.29%），Kaplan-Meier生存分析及Log Rank检验显示，高表达组生存率明显高于低表达组（P<0.05）。结论：miR-363-3p在MM患者血浆中表达下调，其表达水平能评估MM患者病情及临床疗效，还能判断患者预后生存情况。
-
关键词:
- 多发性骨髓瘤 /
- miR-363-3p /
- 临床特征 /
- 预后 /
- 生存时间
Abstract: Objective: To analyze the significance of plasma microribonucleic acid-363-3 p(miR-363-3 p) expression in patients with multiple myeloma(MM), and evaluate its relationship with prognosis.Methods: The clinical data of 106 patients with MM in our hospital was retrospectively analyzed, and 32 healthy subjects with physical examination were included as healthy control group. The difference in plasma miR-363-3 p expression level was recorded in patients with MM and healthy control group. The patients with MM were divided into plasma miR-363-3 p expression level ≥ average value group(high expression group) and miR-363-3 p expression levelResults: The relative expression level of plasma miR-363-3 p of patients with MM was significantly lower than that in healthy control group(P<0.05). There were no significant differences between high expression group and low expression group in terms of gender, age, immunoglobulin typing, DS staging and levels of blood calcium and hemoglobin(P>0.05). But there was a significant difference in International Staging System(ISS) staging between the two groups(P<0.05), and the clinical efficacy of high expression group was significantly higher than that of low expression group(P<0.05). Spearman rank correlation analysis showed that plasma miR-363-3 p expression level in patients with MM was significantly negatively correlated with ISS staging(r=-0.421, P<0.05), and significantly positively correlated with clinical efficacy(r=0.533, P<0.05). At 36 months of follow-up, 31 cases(56.36%) survived in high expression group and 18 cases(35.29%) in low expression group. Kaplan-Meier survival analysis and Log Rank test showed that the survival rate of high expression group was significantly higher than that of low expression group(P<0.05).Conclusion: The expression of miR-363-3 p is down-regulated in the plasma of patients with MM. Its expression level can evaluate the disease condition and clinical efficacy of patients with MM, as well as judge the prognosis and survival of patients. -
Key words:
- multiple myeloma /
- miR-363-3p /
- clinical features /
- prognosis /
- survival time
-
-
[1] Ravi P, Kumar SK, Cerhan JR, et al.Defining cure in multiple myeloma:a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies[J].Blood Cancer J, 2018, 8(3):26.
[2] Galli M, Chatterjee M, Grasso M, et al.Phase I study of the heparanase inhibitor roneparstat:an innovative approach for ultiple myeloma therapy[J].Haematologica, 2018, 103(10):e469-e472.
[3] Pitchiaya S, Heinicke LA, Park JI, et al.Resolving Subcellular miRNA Trafficking and Turnover at Single-Molecule Resolution[J].Cell Rep, 2017, 19(3):630-642.
[4] 刘会永, 李彦, 黄燕.溃疡性结肠炎患者血浆miR-106a和miR-363-3p表达水平的变化及意义[J].国际消化病杂志, 2019, 39(5):341-346.
[5] 中国医师协会血液科医师分会, 中华医学会血液学分会, 中国医师协会多发性骨髓瘤专业委员会.中国多发性骨髓瘤诊治指南(2015年修订)[J].中华内科杂志, 2015, 54(12):1066-1070.
[6] 张兵雷, 周健, 张龚莉, 等.自体造血干细胞移植治疗多发性骨髓瘤的疗效及影响因素的回顾性分析[J].中国实验血液学杂志, 2018, 26(5):1414-1419.
[7] 张凯旋, 蒋端凤, 李晓聃, 等.157例多发性骨髓瘤患者预后因素分析及分期评价[J].实用医学杂志, 2019, 35(14):2238-2242.
[8] Hussein MA, Vrionis FD, Allison R, et al.The role of vertebral augmentation in multiple myeloma:International Myeloma Working Group Consensus Statement[J].Leukemia, 2008, 22(8):1479-1484.
[9] Babion I, Snoek BC, Novianti PW, et al.Triage of high-risk HPV-positive women in population-based screening by miRNA expression analysis in cervical scrapes;a feasibility study[J].Clin Epigenetics, 2018, 10:76.
[10] 梁忆华, 钟海波, 张敏.miR-363通过靶向HMGA2调控非小细胞肺癌的细胞生长与侵袭[J].西部医学, 2019, 31(1):13-18.
[11] Li WZ, Zou Y, Song ZY, et al.Long non-coding RNA SNHG5 affects the invasion and apoptosis of renal cell carcinoma by regulating the miR-363-3p-Twist1 interaction[J].Am J Transl Res, 2020, 12(2):697-707.
[12] Gowda PS, Wildman BJ, Trotter TN, et al.Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression[J].Mol Cancer Res, 2018, 16(7):1138-1148.
[13] Chen Y, Hao JX, Zhao J, et al.Long non-coding RNA PCAT1 facilitates cell growth in multiple myeloma through an MTDH-mediated AKT/β-catenin signaling pathway by sponging miR-363-3p[J].RSC Adv, 2019, 9(58):33834-33842.
[14] 董亚青, 马艳萍.外周血单核细胞/淋巴细胞比值在接受硼替佐米治疗的初诊多发性骨髓瘤患者预后中的价值[J].临床血液学杂志, 2019, 32(5):375-380.
[15] Yu T, Chaganty B, Lin L, et al.VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo[J].Blood Cancer J, 2020, 10(11):110.
[16] Sun YL, Guan XL, Zhang P, et al.Pol-miR-363-3p plays a significant role in the immune defense of Japanese flounder Paralichthys olivaceus against bacterial and viral infection[J].Fish Shellfish Immunol, 2020, 104:439-446.
[17] Zhu B, Chen H, Zhang X, et al.Serum miR-30 d as a novel biomarker for multiple myeloma and its antitumor role in U266 cells through the targeting of the MTDH/PI3K/Akt signaling pathway[J].Int J Oncol, 2018, 53(5):2131-2144.
-
计量
- 文章访问数: 224
- PDF下载数: 189
- 施引文献: 0
下载: